Search results for " Investing"

Article Taking a “Development-by-Design” Approach to Cell Therapies
Jun 15, 2015 By Agnes Shanley BioPharm International eBooks Volume 28, Issue 13 Whether outsourcing or developing cell therapies in-house, success demands a focus on quality, c…

Article Biomanufacturing Outsourcing Globalization Continues
Larger biologics developers often prefer to keep process development capabilities in-house, even as they avoid investing in manufacturing facilities. This strategy enables them to save on up-front fac…

Article Fermentation for the Future
Improving efficiency, value chain, quality, and protein complexity with advanced bioprocess development. Jan 01, 2015 By Cynthia Challener, PhD Microorganisms—bacteria and yeast—have b…

Article What Drove Biopharma Development in 2014?
Process Development Forum (PDF) featured a myriad of topics at the forefront of biopharmaceutical development. But some issues stood out as garnering the most attention from readers in 2014. One of …

Article Improving PAT for Biologics
The complexity of biopharma processes requires innovative solutions. Dec 01, 2014 By Cynthia Challener, PhD BioPharm International A key component of the quality-by-design (QbD) ap…

Article Trends in Single-use Bioreactors
Representatives from industry supplier companies address innovations, reliability, barriers to adoption, and the role of singIe-use bioreactors in bioprocessing. By: Randi Hernandez Whil…

Article Optimizing Resin Performance with Disposable Chromatography Solutions
In addition, looking at ways to improve on Protein A technology, we are investing in the development of newer-affinity resins (including affinity resins based on Protein L) for the purification of a n…

Article Biopharma Manufacturers Respond to Ebola Crisis
Demand for new therapies and vaccines spotlights production challenges. Oct 1, 2014 By: Jill Wechsler BioPharm International Volume 27, Issue 10, pp. 8-9 The development of new tr…

Article Relationship Building at Top of Mind for Clients
Annual study shows technical expertise is not enough. Aug 1, 2014 By: Eric Langer BioPharm International Volume 27, Issue 8, pp. 12-14 Contract manufacturing organizations (CMOs) shou…

Article Single-Domain Antibodies for Brain Targeting
Single-domain antibodies are emerging as credible alternatives due to their target specificity, high affinity, and cost-effective recombinant production. Smaller recombinant antibody fragments a…

Previous PageNext Page